|
Demyelinating Diseases
|
0.200 |
Biomarker
|
group |
RGD |
A mutation in the gene encoding mitochondrial Mg²+ channel MRS2 results in demyelination in the rat.
|
21253565 |
2011 |
|
Cerebral Infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
Secondary end-points include: 90-day functional independence (mRS ≤2), mRS shift stratified for treatment with IV rt-PA at 90 days, infarct volume on 24 h CT or MRI, early dramatic response (NIHSS 0-2 or improvement ≥8 points) at 24 h, vessel recanalization evaluated by CTA or MRA at 24 h, and the post-procedure rate of successful reperfusion (defined as a modified Treatment in Cerebral Infarction 2b or greater).
|
31793395 |
2019 |
|
Cerebrovascular accident
|
0.020 |
Biomarker
|
group |
BEFREE |
Good outcome was defined as an mRS <1, whereas patients defined as having a poor outcome had either an mRS ≥2 or died shortly after the stroke event.
|
29074424 |
2018 |
|
Acute Cerebrovascular Accidents
|
0.020 |
Biomarker
|
disease |
BEFREE |
<i>Clinical outcome:</i> 42% (132/315) of NASA patients demonstrated a 90 day mRS ≤2 compared with 37% (SWIFT) and 40% (TREVO 2).
|
30037956 |
2018 |
|
Cerebral Infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
Overall, compared with control intervention, simvastatin intervention had no influence on delayed ischaemic deficit (RR=0.99; 95% CI=0.78 to 1.27; P=0.96), delayed cerebral infarction (RR=1.17; 95% CI=0.60 to 2.29; P=0.65), mRS≤2 (RR=0.97; 95% CI=0.87 to 1.09; P=0.61), vasospasm (RR=0.79; 95% CI=0.49 to 1.29; P=0.35), ICU stay (Std. mean difference=0.04; 95% CI=-0.54 to 0.63; P=0.88), hospital stay (Std. mean difference=0.01; 95% CI=-0.13 to 0.14; P=0.90) and mortality (RR=0.71; 95% CI=0.25 to 2.05; P=0.53) after aneurysmal subarachnoid hemorrhage.
|
28966073 |
2017 |
|
Cerebrovascular accident
|
0.020 |
Biomarker
|
group |
BEFREE |
Eighty-six cases suffering from cerebral infarction within 14 days were assigned into the good outcome group (n = 47) and the bad outcome group (n = 39) depending on the modified Rankin Scale scores (mRS ≤2 at 90 days following stroke onset was good outcome).
|
28017496 |
2017 |
|
Acute Cerebrovascular Accidents
|
0.020 |
Biomarker
|
disease |
BEFREE |
A systematic review and meta-analysis of preventive antibiotics`effect on the incidence of infection, favorable outcome (mRS≤2) and mortality in patients with acute stroke is performed with relevant randomized controlled trials.
|
29049353 |
2017 |
|
Deglutition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The poor outcome was defined as a condition that includes the mRS ≥2 and/or dysphagia at one year after onset.
|
30875528 |
2019 |
|
Ischemic stroke
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our meta-analysis suggested that smoking was not associated with good functional outcome (mRS ≤ 2) at 3 months in patients with acute ischemic stroke who were treated with intravenous thrombolysis.
|
31219582 |
2019 |
|
Subarachnoid Hemorrhage
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compared to control intervention, simvastatin intervention was found to have no influence on delayed ischaemic deficit, delayed cerebral infarction, mRS≤2, vasospasm, ICU stay, hospital stay, and mortality in patients with acute aneurysmal subarachnoid hemorrhage.
|
28966073 |
2017 |
|
CADASIL Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we measured vitamin D levels in 56 Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) patients (mean age 49.9) with no or minimal disability (modified Ranking Score, mRS ≤2) and in 56 age, sex and seasonality matched healthy controls.
|
28378255 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Even with the most conservative Bonferroni adjustment, two 2-SNP-haplotypes in SLC41A2 and MRS2 region were significantly associated with T2D risk (rs12582312-rs10861279: P = 0.0006; rs1056285-rs7738943: P = 0.002).
|
25733456 |
2015 |
|
Familial (FPAH)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Corticobasal degeneration can have a familial presentation; the role of MRS2 and ZHX2 gene products in CBD should be further investigated.
|
23867865 |
2013 |
|
Deuteranomaly
|
0.010 |
Biomarker
|
disease |
BEFREE |
Corticobasal degeneration can have a familial presentation; the role of MRS2 and ZHX2 gene products in CBD should be further investigated.
|
23867865 |
2013 |